Sugi Predict

Sugi Predict / Compounds / SCHEMBL1477908

SCHEMBL1477908

SCHEMBL1477908

O=C(Cl)C1CCCCCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 1/20 0.58
▸ CES1 P23141 1/20 0.58
▸ HDAC8 Q9BY41 1/20 0.48
▸ HDAC6 Q9UBN7 1/20 0.48
▸ TSHR P16473 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ HSD11B1 P28845 6/20 0.41
▸ EPHX1 P07099 6/20 0.39
▸ RECQL P46063 1/20 0.39
▸ CHRNB2 P17787 1/20 0.38
▸ CHRNA3 P32297 1/20 0.38
▸ CHRNA4 P43681 1/20 0.38
▸ CHRNB3 Q05901 1/20 0.38
▸ CHRNA6 Q15825 1/20 0.38
▸ HSD11B2 P80365 1/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ MAPT P10636 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16317826 1.00 CES2 (0.58) CES2CES1HDAC8HDAC6TSHR
SCHEMBL9013430 1.00 CES2 (0.58) CES2CES1HDAC8HDAC6TSHR
SCHEMBL13368687 1.00 CES2 (0.58) CES2CES1HDAC8HDAC6TSHR
SCHEMBL8294928 1.00 CES2 (0.58) CES2CES1HDAC8HDAC6TSHR
SCHEMBL2154567 1.00 CES2 (0.58) CES2CES1HDAC8HDAC6TSHR
SCHEMBL1420 1.00 — —
SCHEMBL9010935 1.00 CES2 (0.58) CES2CES1HDAC8HDAC6TSHR
SCHEMBL21391824 0.97 CES2 (0.55) CES2CES1HDAC8HDAC6TSHR
Methane SCHEMBL27878577 0.97 CES2 (0.55) CES2CES1HDAC8HDAC6TSHR
Methane SCHEMBL28248397 0.97 CES2 (0.55) CES2CES1HDAC8HDAC6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113862058-B Lubricating oil composition and preparation method thereof 中国石油化工股份有限公司（CN） 2023-01-13 — — CN claimed
CN-113861031-A Ester compound, preparation method and application thereof, and lubricating oil composition 中国石油化工股份有限公司 2021-12-31 — — CN claimed
CN-113862058-A Lubricating oil composition and preparation method thereof 中国石油化工股份有限公司 2021-12-31 — — CN claimed
CN-113861032-A Ester compound, preparation method and application thereof, and lubricating oil composition 中国石油化工股份有限公司 2021-12-31 — — CN claimed
CN-113754666-A Benzopyrazine compound and synthesis method thereof 凯美克(上海)医药科技有限公司 2021-12-07 — — CN claimed
EP-2731923-B1 PROCESS FOR PREPARING CYCLOHEPTENE BASF SE (DE) 2015-09-09 — — EP claimed
US-20130018205-A1 PROCESS FOR PREPARING CYCLOHEPTENE BASF SE (DE) 2013-01-17 — — US claimed
WO-2010115869-A1 PROPOFOL PHOSPHONYL DERIVATIVES, SYNTHESIS, AND USE IN LONG ACTING FORMULATIONS SEPS PHARMA N.V. (BE) 2010-10-14 — — WO claimed
US-20080064876-A1 Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione CELGENE CORPORATION 2008-03-13 — — US claimed
WO-2007136640-A2 PROCESSES FOR THE PREPARATION OF SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLE-1,3-DIONE CELGENE CORPORATION (US) 2007-11-29 — — WO claimed
US-20260102380-A1 Synthesis and Characterization of Cyclic Hydrocarbon Esters of Everolimus BIOTRONIK AG (CH) 2026-04-16 — — US disclosed
US-20250109139-A1 TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) 2025-04-03 — — US disclosed
US-12102648-B2 Orally-bioavailable nucleoside analogs VenatoRx Pharmaceuticals, Inc. (US) 2024-10-01 — — US disclosed
CN-118139868-A Orally bioavailable nucleoside analogs 维纳拓尔斯制药公司 2024-06-04 — — CN disclosed
EP-4355755-A1 ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS Venatorx Pharmaceuticals, Inc. (US) 2024-04-24 — — EP disclosed
US-4138581-A BRONCHODILATOR AGENTS, ADRENERGIC STIMULANTS STERLING DRUGS INC. (US) 1979-02-06 — — US disclosed
US-4008217-A HERBICIDE THE UPJOHN COMPANY (US) 1977-02-15 — — US disclosed
US-4001218-A BACTERICIDES BAYER AKTIENGESELLSCHAFT (DT) 1977-01-04 — — US disclosed
US-3982011-A ANTIBIOTICS, ANIMAL GROWTH PROMOTERS BAYER AKTIENGESELLSCHAFT (DT) 1976-09-21 — — US disclosed
US-3931153-A BACTERICIDE BAYER AKTIENGESELLSCHAFT (DT) 1976-01-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018205-A1 PROCESS FOR PREPARING CYCLOHEPTENE DHPS, FDFT1, MTHFD2 CES2 468/4885CES1 589/4885HDAC8 2324/4885
US-20250109139-A1 TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF PARK7, HADH, BDNF CES2 1885/4885CES1 1172/4885HDAC8 533/4885
US-12102648-B2 Orally-bioavailable nucleoside analogs SLC29A2, SLC29A1, PNP CES2 758/4885CES1 398/4885HDAC8 2684/4885
US-20080064876-A1 Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione TNF, DHPS, IDO1 CES2 3689/4885CES1 2359/4885HDAC8 2752/4885
US-20260102380-A1 Synthesis and Characterization of Cyclic Hydrocarbon Esters of Everolimus MTOR, VEGFA, RICTOR CES2 2081/4885CES1 1252/4885HDAC8 2386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.